Skip to main content
Log in

Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The frequency, severity, and outcome of flutamide-induced hepatic injury were prospectively evaluated in 55 patients with prostate cancer who received 125 mg of flutamide 3 times a day (daily dose: 375 mg) combined with an agonistic analogue of luteinizing hormone-releasing hormone. In addition, we examined plasma and urine concentrations of flutamide and its major metabolites 4 weeks after the beginning of flutamide therapy, and evaluated their significance in predicting flutamide-induced hepatic dysfunction. Hepatic function could be assessed in 50 patients and hepatic dysfunction during therapy was observed in 9 patients (18%); 3 patients (6%) were classified as having moderate liver dysfunction and 6 (12%) were classified as having mild liver dysfunction. The steady-state plasma levels of flutamide and its biologic active metabolite, hydroxyflutamide (OH-Flu), were not related to hepatic dysfunction. However, the concentration of another major metabolite, 4-nitro-3-(trifluoromethyl)phenylamine (FLU-1) was considerably higher in 2 patients who developed clinically significant hepatic dysfunction. These findings suggest that clinically significant hepatic dysfunction could be induced in patients with compromised flutamide metabolism, which leads to a high concentration of FLU-1. Based on results of this study, we propose that plasma FLU-1 levels are one of the predictive factors for flutamide-induced hepatic dysfunction. This hypothesis will be confirmed in a large-scale study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989

    Google Scholar 

  2. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, Labrie F: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 92: 465-470, 1992

    Google Scholar 

  3. Cetin M, Demirci D, Unal A, Altinbas M, Guven M, Uluhizarci K: Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol 18: 137-140, 1991

    Google Scholar 

  4. Cortes MG, Andrade RJ, Lucena MI, Martinez HS, Fermandez MC, Ferrer T, Martin-Vivaldi R, Pelaez G, Suarez F, Rosemary-Gomez M, Montero JL, Fraga E, Camargo R, Alcantara R, Pizarro MA, Garcia-Ruiz E: Rev Esp Enferm Dig 93: 428-432, 2001

    Google Scholar 

  5. Yamaguchi A, Ozono S, Kitauchi T, Nakanou I, Torimoto K, Fujimoto K, Hirao Y: Study of flutamide-induced liver disorders. Nishinihon J Urol 63: 469-471, 2001

    Google Scholar 

  6. Nakagawa Y, Koyama M, Matsumoto M: Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer. Acta Urol Jpn 45: 821-826, 1999

    Google Scholar 

  7. Wada T, Ueda M, Abe K, Kobari T, Yamazaki H, Nakata J, Ikemoto I, Ohishi Y, Aizawa Y: Risk factor of liver disorders caused by flutamide — statistical analysis using multivariate logistic regression analysis. Acta Urol Jpn 45: 521-526, 1999

    Google Scholar 

  8. Zimmerman HJ: Drug-induced liver disease. In: E.R. Schiff, M.F. Sorrell, W.C. Maddley (eds). Diseases of the Liver. Lippincott-Raven, Philadelphia, 1999, pp 973-1064

    Google Scholar 

  9. Kachen B, Buxbaum S: Disposition of a new, nonsteroid, antiandrogen, α-α-αtrifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 41: 373-379, 1975

    Google Scholar 

  10. Schulz M, Schmoldt A, Donn F, Becker H: The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 34: 633-636, 1988

    Google Scholar 

  11. Radwanski E, Perentesis G, Symchowicz S, Zampaglione N: Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. J Clin Pharmacol 29: 554-558, 1989

    Google Scholar 

  12. Asakawa N, Koyama M, Hashimoto Y, Yamashita K: Studies on the metabolic fate of flutamide (I): Plasma concentration after single administration and protein binding in rats. Xenobio Metabol Dispos 10: 447-453, 1995

    Google Scholar 

  13. Asakawa N, Koyama M, Hashimoto Y, Yamashita K: Studies on the metabolic fate of flutamide (4): Biliary excretion, enterohepatic circulation, absorption from gastro-intestinal tract, metabolism and drug-metabolizing enzymes induction in rats. Xenobio Metabol Dispos 10: 470-483, 1995

    Google Scholar 

  14. Jewett HJ: The present status of radical prostatectomy for stage A and B prostate cancer. Urol Clin North Am 2: 105-124, 1975

    Google Scholar 

  15. Siest G, Schieie F, Galteau MM, Panek E, Steinmetz J, Fagnani F, Gueguen R: Aspartate aminotransferase and alanine aminotransferase activities in plasma: Statistical distributions, individual variations, and reference values. Clin Chem 21: 1077-1087, 1975

    Google Scholar 

  16. Kuntz E, Kuntz H-D: Hepatology: Principles and Practice. Springer-Verlag, Berlin, 2001, pp 77-84

    Google Scholar 

  17. Shet MS, Mcphaul M, Ficher CW, Stallings NR, Estabrook RW: Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Dispos 25: 1298-1303, 1997

    Google Scholar 

  18. Anjum S, Swan SK, Lambrecht LJ, Radwanski E, Cutler DL, Affrime MB, Halstenson CE: Pharmacokinetics of flutamide in patients with renal insufficiency. Br J Pharmacol 47: 43-47, 1999

    Google Scholar 

  19. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, Pessayre D: Toxicity of antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269: 954-962, 1994

    Google Scholar 

  20. Wysowski DK, Fourcroy JL: Flutamide hepatotoxicity. J Urol 155: 209-212, 1996

    Google Scholar 

  21. Kojima M, Kamoi K, Ukimura O, Fujito A, Nakao M, Tanaka S, Miyashita H, Iwamoto N, Ohe H, Kitamori T, Date S, Kitamura K, Araki H, Aoki T, Imada N, Takada H, Imaide Y, Mikami K, Uchida M, Saitoh M, Miki T: Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study. Int J Urol 9: 42-46, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aizawa, Y., Ikemoto, I., Kishimoto, K. et al. Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. Mol Cell Biochem 252, 149–156 (2003). https://doi.org/10.1023/A:1025560513308

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025560513308

Navigation